Modi N - Search Results

1

Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.

Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulder E, Wigal S. Swanson J, et al. Among authors: modi n. Arch Gen Psychiatry. 2003 Feb;60(2):204-11. doi: 10.1001/archpsyc.60.2.204. Arch Gen Psychiatry. 2003. PMID: 12578439 Clinical Trial.

2

Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation.

Modi NB, Lindemulder B, Gupta SK. Modi NB, et al. J Clin Pharmacol. 2000 Apr;40(4):379-88. doi: 10.1177/00912700022009080. J Clin Pharmacol. 2000. PMID: 10761165 Clinical Trial.

3

Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system.

Modi NB, Wang B, Noveck RJ, Gupta SK. Modi NB, et al. J Clin Pharmacol. 2000 Oct;40(10):1141-9. J Clin Pharmacol. 2000. PMID: 11028253 Clinical Trial.

4

Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects.

Modi NB, Wang B, Hu WT, Gupta SK. Modi NB, et al. Biopharm Drug Dispos. 2000 Jan;21(1):23-31. doi: 10.1002/1099-081x(200001)21:1<23::aid-bdd212>3.0.co;2-v. Biopharm Drug Dispos. 2000. PMID: 11038435 Clinical Trial.

5

Application of in vitro-in vivo correlations (IVIVC) in setting formulation release specifications.

Modi NB, Lam A, Lindemulder E, Wang B, Gupta SK. Modi NB, et al. Biopharm Drug Dispos. 2000 Nov;21(8):321-6. doi: 10.1002/bdd.248. Biopharm Drug Dispos. 2000. PMID: 11514951

6

Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina.

Gupta S, Modi NB, Sathyan G, Ho Pl PL, Aarons L. Gupta S, et al. Biopharm Drug Dispos. 2002 Jan;23(1):17-31. doi: 10.1002/bdd.289. Biopharm Drug Dispos. 2002. PMID: 11891670

7

Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking.

Kang D, Verotta D, Krecic-Shepard ME, Modi NB, Gupta SK, Schwartz JB. Kang D, et al. Clin Pharmacol Ther. 2003 Jan;73(1):31-40. doi: 10.1067/mcp.2003.21. Clin Pharmacol Ther. 2003. PMID: 12545141

8

Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation.

Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S. Modi NB, et al. J Clin Pharmacol. 2006 Mar;46(3):301-9. doi: 10.1177/0091270005284850. J Clin Pharmacol. 2006. PMID: 16490806 Clinical Trial.

9

Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder.

Wigal SB, Gupta S, Greenhill L, Posner K, Lerner M, Steinhoff K, Wigal T, Kapelinski A, Martinez J, Modi NB, Stehli A, Swanson J. Wigal SB, et al. J Child Adolesc Psychopharmacol. 2007 Apr;17(2):153-64. doi: 10.1089/cap.2007.0043. J Child Adolesc Psychopharmacol. 2007. PMID: 17489710 Clinical Trial.

10

Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects.

Modi NB, Nath R, Staehr P, Gupta SK, Aquilina JW, Rivas D. Modi NB, et al. J Clin Pharmacol. 2009 Jun;49(6):634-42. doi: 10.1177/0091270009333486. Epub 2009 Apr 23. J Clin Pharmacol. 2009. PMID: 19389877 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

668 results

Search Page

Filters